These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 7379368)

  • 1. The complement system in hemolytic-uremic syndrome in childhood.
    Monnens L; Molenaar J; Lambert PH; Proesmans W; van Munster P
    Clin Nephrol; 1980 Apr; 13(4):168-71. PubMed ID: 7379368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breakdown products of C3 and factor B in hemolytic-uremic syndrome.
    Kim Y; Miller K; Michael AF
    J Lab Clin Med; 1977 Apr; 89(4):845-50. PubMed ID: 845484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How do complement components and fragments affect cellular immunological function?
    Gelfand JA
    J Trauma; 1984 Sep; 24(9 Suppl):S118-24. PubMed ID: 6332921
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.
    Wouters D; Brouwer MC; Daha MR; Hack CE
    Mol Immunol; 2008 Apr; 45(7):1893-9. PubMed ID: 18054386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteins involved in the activation and control of the two pathways of human complement.
    Reid KB
    Biochem Soc Trans; 1983 Jan; 11(1):1-12. PubMed ID: 6298023
    [No Abstract]   [Full Text] [Related]  

  • 7. Humoral immune system and ulcerative colitis activity. II. Complement level.
    Hermanowicz A; Sliwiński Z; Nawarska Z; Banaś B
    Arch Immunol Ther Exp (Warsz); 1984; 32(5):509-14. PubMed ID: 6152530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Complement system during hemofiltration in patients with multiple organ failure].
    Iakovleva II; Timokhov VS; Lialikova GV; Semenov VN; Moroz VV
    Anesteziol Reanimatol; 1999; (1):23-6. PubMed ID: 10199040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-complement therapy for glomerular diseases.
    Bomback AS
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):152-8. PubMed ID: 24602464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement ligand-receptor interactions that mediate biological responses.
    Fearon DT; Wong WW
    Annu Rev Immunol; 1983; 1():243-71. PubMed ID: 6242465
    [No Abstract]   [Full Text] [Related]  

  • 11. Circulating immune complexes and complement levels in hemophilic children.
    Verroust F; Adam C; Kourilsky O; Allain JP; Verroust P
    J Clin Lab Immunol; 1981 Sep; 6(2):127-30. PubMed ID: 6912882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of complement with the red-cell membrane.
    Rosse WF
    Semin Hematol; 1979 Apr; 16(2):128-39. PubMed ID: 384519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible C1q bypass loop activation in the haemolytic uraemic syndrome.
    Nolin L; O'Regan S; Pelletier M; Rivard GE; Mongeau JG; Robitaille P
    Clin Exp Immunol; 1979 Jan; 35(1):107-11. PubMed ID: 371879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
    Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
    Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible contribution of the complement system to the inflammatory state.
    Hadding U
    Agents Actions Suppl; 1980; 7():24-32. PubMed ID: 7018199
    [No Abstract]   [Full Text] [Related]  

  • 17. [Persistent activation of C3 in the hemolytic uremic syndrome].
    Gonzalo A; Sarrias J; Alsina J
    Rev Clin Esp; 1977 May; 145(4):281-3. PubMed ID: 866752
    [No Abstract]   [Full Text] [Related]  

  • 18. Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome.
    Ferraris JR; Ferraris V; Acquier AB; Sorroche PB; Saez MS; Ginaca A; Mendez CF
    Clin Exp Immunol; 2015 Jul; 181(1):118-25. PubMed ID: 25677399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on evaluating complement in hemolytic uremic syndrome.
    Kavanagh D; Goodship TH
    Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):565-71. PubMed ID: 18089972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemolytic uremic syndrome with hypocomplementemia and deposits of IgM and C3 in the involved renal tissue.
    Gonzalo A; Mampaso F; Gallego N; Bellas C; Segui J; Ortuño J
    Clin Nephrol; 1981 Oct; 16(4):193-9. PubMed ID: 7028337
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.